Expert Ratings for Timken

Analysts have provided the following ratings for Timken (NYSE:TKR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

Analysts have provided the following ratings for Timken (NYSE:TKR) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 0 4 1 0
Last 30D 0 0 1 0 0
1M Ago 1 0 0 1 0
2M Ago 0 0 1 0 0
3M Ago 0 0 2 0 0

According to 6 analyst offering 12-month price targets in the last 3 months, Timken has an average price target of $89.33 with a high of $100.00 and a low of $74.00.

Below is a summary of how these 6 analysts rated Timken over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 4.56% from the previous average price target of $93.60.

Stay up to date on Timken analyst ratings.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Musk Shrugs Off ‘Stock Market Craziness,’ COVID Resurgence Haunts Nio But Li Auto Shines, Canoo Sues Former Executives And More: Biggest EV Stories Of The Week

Electric vehicle stocks closed the final trading week of the year on a mixed note amid the volatility in the broader market. Tesla, Inc. (NASDAQ: TSLA) swung wildly before snapping three straight weeks of losses and closing just higher for the week.

GOEV

Read More

Bristol Myers’ Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion

On Monday, the FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Reblozyl (luspatercept-aamt) for anemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients with very low-to-intermediate-risk myelodysplastic syndromes (MDS) who may require regular 

BMY